Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

We expect Amgen AMGN to beat expectations when it reports second-quarter 2025 results on Aug. 5 after market close. In the ...

Amgen: Reducing My Price Target, Reiterate Buy After A Solid Q1 May 04, 2025 10:30 AM ET Amgen Inc. (AMGN) Stock AMGN 3 Comments Mike Zaccardi, CFA, CMT 7.96K Follower s Play (7min) ...

Long Trade IdeaEnter your long position between 297.78 (yesterday's intra-day low) and 304.07 (yesterday's intra-day high).Market Index Analys ...

The Zacks Medical - Biomedical and Genetics industry, to which Amgen belongs, has lost 0.6% over this period. Now the key question is: Where could the stock be headed in the near term?

(NASDAQ:AMGN) share price is up 22% in the last three years, that falls short of the market return. Disappointingly, the ...

Amgen (NASDAQ: AMGN) is doing something unusual in 2025. Here's why this $150 billion pharmaceutical powerhouse deserves a closer look by investors of all stripes. Amgen delivered stellar first ...

Amgen is dealing with the threat of several fast-approaching patent expirations. The drugmaker's dividend streak is impressive, and the stock is trading at reasonable levels. Amgen (NASDAQ: AMGN) ...

Amgen (NASDAQ:AMGN – Get Free Report) had its target price increased by equities research analysts at UBS Group from $315.00 to $319.00 in a report issued on Monday,Benzinga reports. The firm ...

Amgen (AMGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.